• Medicine Name– Taffic
  • API- Bictegravir, Emtricitabine and Tenofovir Alafenamide
  • Packaging- Tablets
  • Strength- 50 mg/200 mg /25 mg
  • Manufactured by- Hetero Healthcare Ltd.
Get an Enquiry


This combination medicine consists bictegravir, an integrase strand transfer inhibitor (INSTI) for the human immunodeficiency virus type 1 (HIV-1), and emtricitabine, FTC, and tenofovir alafenamide, TAF, which are both HIV-1 nucleoside analog reverse transcriptase inhibitors (NRTIs). Taffic tablet is used as a complete regimen to treat HIV-1 infection in adult patients who have not previously taken antiretroviral treatment, or to replace the current antiretroviral regimen in individuals who are virologically suppressed (HIV-1 RNA below 50 copies per mL) on a stable antiretroviral regimen for at least 90 days, without a history of treatment failure, and without any substitutions linked to resistance to the drug’s individual components.

Dosage and Side Effects

The Taffic tablet is a three-drug fixed dosage combination (FDC) medication that includes 25 mg of tenofovir alafenamide (TAF), 200 mg of emtricitabine (FTC), and 50 mg of bictegravir (BIC). One tablet taken orally once a day, with or without food, is the suggested dosage. Patients should take Taffic according to a regular schedule and refrain from skipping doses as this may lead to the emergence of resistance.

The three most often mentioned adverse effects of Taffic are headache, diarrhoea, and nausea.

Warning and Precautions

  • Before or when starting bictegravir emtricitabine and tenofovir alafenamide, patients should undergo testing for hepatitis B virus infection.

  • Prior to initiating or during Taffic treatment, it’s crucial to evaluate serum creatinine, estimated creatinine clearance, urine glucose, and urine protein. Individuals with chronic kidney disease should also have their serum phosphorus levels assessed.

  • The use of bictegravir emtricitabine tenofovir treatment is not advisable for patients whose estimated creatinine clearance falls below 30 mL per minute.

  • Patients with severe hepatic impairment (Child-Pugh Class C) are not recommended for Taffic therapy.

  • Individuals diagnosed with HIV-1 should be screened for chronic hepatitis B virus (HBV) infection before starting antiretroviral therapy.

  • For patients coinfected with HIV-1 and HBV who discontinue taffic tablets, thorough clinical and laboratory follow-up for several months after stopping treatment is highly recommended.

  • Patients with impaired renal function taking tenofovir prodrugs or nephrotoxic agents, including non-steroidal anti-inflammatory drugs, are at higher risk of renal-related adverse reactions.

  • Suspension of treatment with bictegravir emtricitabine tenofovir alafenamide is advised for any patient displaying clinical or laboratory signs indicating lactic acidosis or significant hepatotoxicity.

  • Inform patients about an antiretroviral pregnancy registry aimed at monitoring fetal outcomes in pregnant women exposed to Taffic.

  • Women with HIV-1 infection are advised against breastfeeding due to the risk of transmitting HIV-1 through breast milk to the baby.


Taffic: What is it?

Three drugs are combined in one daily pill called Taffic: bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg).

Which strengths of Taffic are available?

Tablets containing 50 mg of bictegravir (or 52.5 mg of bictegravir sodium), 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide (or 28 mg of tenofovir alafenamide fumarate) are the form in which Taffic is delivered. 

How does one administer Taffic?

Usually, tacfic is supplied in the form of oral (by mouth) pills.

What kind of drug is Taffic?

Specifically, taffic is a kind of antiretroviral combo drug.